Cardiovascular Pharmacogenomics-Implications for Patients With CKD

Advances in Chronic Kidney Disease

Volumn 23, Issue 2, 2016, Pages 82-90

  Cavallari, Larisa H ^a,b,c   Mason, Darius L ^a,b,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Clopidogrel; Genotype; Pharmacogenomics; Simvastatin; Warfarin

Indexed keywords

ATENOLOL; ATORVASTATIN; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CLOPIDOGREL; CREATINE KINASE; CYCLOSPORIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; METOPROLOL SUCCINATE; MEVINOLIN; NEBIVOLOL; PITAVASTATIN; PRASUGREL; PRAVASTATIN; PROPRANOLOL; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; TICAGRELOR; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450; IMMUNOSUPPRESSIVE AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; SOLUTE CARRIER PROTEIN; TICLOPIDINE; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; AGE; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BODY SIZE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSFORMATION; DRUG TRANSPORT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MUSCLE INJURY; MYALGIA; MYOPATHY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SUDDEN CARDIAC DEATH; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHENOTYPE;

ADRENERGIC BETA-ANTAGONISTS; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; PRECISION MEDICINE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RENAL INSUFFICIENCY, CHRONIC; SOLUTE CARRIER PROTEINS; TICLOPIDINE; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84959860595     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2015.12.001     Document Type: Review

References (76)

1. 2014 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States 2014, United States Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351(13):1296-1305.
3. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164(6):659-663.
4. Collins F.S., Varmus H. A new initiative on precision medicine. N Engl J Med 2015, 372(9):793-795.
5. Relling M.V., Klein T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011, 89(3):464-467.
6. Johnson J.A., Gong L., Whirl-Carrillo M., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011, 90(4):625-629.
7. Ramsey L.B., Johnson S.G., Caudle K.E., et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014, 96(4):423-428.
8. Scott S.A., Sangkuhl K., Stein C.M., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013, 94(3):317-323.
9. Limdi N.A., Limdi M.A., Cavallari L., et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010, 56(5):823-831.
10. Melloni C., Cornel J.H., Hafley G., et al. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: insights from the TRILOGY ACS Trial [e-pub ahead of print]. Eur Heart J Acute Cardiovasc Care 2015, accessed December 31. 10.1177/2048872615598631.
11. Chan K.E., Edelman E.R., Wenger J.B., Thadhani R.I., Maddux F.W. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015, 131(11):972-979.
12. Ageno W., Gallus A.S., Wittkowsky A., et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl):e44S-88S.
13. Chou C.Y., Kuo H.L., Wang S.M., et al. Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol Dial Transplant 2010, 25(4):1225-1230.
14. Wang T.K., Sathananthan J., Marshall M., Kerr A., Hood C. Relationships between anticoagulation, risk scores and adverse outcomes in dialysis patients with atrial fibrillation [e-pub ahead of print]. Heart Lung Circ 2015, http://dx.doi.org/10.1016/j.hlc.2015.08.012, accessed December 31.
15. Dahal K., Kunwar S., Rijal J., Schulman P., Lee J. Stroke, major bleeding and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies [e-pub ahead of print]. Chest 2015, http://dx.doi.org/10.1378/chest.15-1719, accessed December 31.
16. Shen J.I., Montez-Rath M.E., Lenihan C.R., Turakhia M.P., Chang T.I., Winkelmayer W.C. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 2015, 66(4):677-688.
17. Cavallari L.H., Perera M.A. The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol 2012, 8(4):563-576.
18. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352(22):2285-2293.
19. Mega J.L., Walker J.R., Ruff C.T., et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015, 385(9984):2280-2287.
20. Gage B.F., Eby C., Johnson J.A., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008, 84(3):326-331.
21. Klein T.E., Altman R.B., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360(8):753-764. International Warfarin Pharmacogenetics C.
22. Kimmel S.E., French B., Kasner S.E., et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013, 369(24):2283-2293.
23. Pirmohamed M., Burnside G., Eriksson N., et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013, 369(24):2294-2303.
24. Holbrook A., Schulman S., Witt D.M., et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl):e152S-184S.
25. Meschia J.F., Bushnell C., Boden-Albala B., et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014, 45(12):3754-3832.
26. Nutescu E.A., Drozda K., Bress A.P., et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 2013, 33(11):1156-1164.
27. Nutescu E., Duarte J., Cheng W., et al. Novel genotype guided personalized warfarin service improves outcomes in an ethnically diverse population. Circulation 2014, 130(2 Suppl):A16119.
28. Washam J.B., Herzog C.A., Beitelshees A.L., et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation 2015, 131(12):1123-1149.
29. Fox C.S., Muntner P., Chen A.Y., et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010, 121(3):357-365.
30. Ahmed S., Michael Gibson C., Cannon C.P., Murphy S.A., Sabatine M.S. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thrombolysis 2011, 31(4):493-500.
31. Best P.J., Steinhubl S.R., Berger P.B., et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008, 155(4):687-693.
32. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(4):354-362.
33. Mega J.L., Simon T., Collet J.P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010, 304(16):1821-1830.
34. Jneid H., Anderson J.L., Wright R.S., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012, 60(7):645-681.
35. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119(19):2553-2560.
36. Wallentin L., James S., Storey R.F., et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010, 376(9749):1320-1328.
37. Weitzel K.W., Elsey A.R., Langaee T.Y., et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 2014, 166C(1):56-67.
38. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25 Suppl 2):S1-S45.
39. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377(9784):2181-2192.
40. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360(14):1395-1407.
41. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353(3):238-248.
42. Wanner C., Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014, 85(6):1303-1309. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group M.
43. Stroes E.S., Thompson P.D., Corsini A., et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J 2015, 36(17):1012-1022.
44. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80(6):565-581.
45. Group S.C., Link E., Parish S., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359(8):789-799.
46. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010, 87(1):130-133.
47. Brunham L.R., Lansberg P.J., Zhang L., et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012, 12(3):233-237.
48. Puccetti L., Ciani F., Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010, 211(1):28-29.
49. Voora D., Shah S.H., Spasojevic I., et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54(17):1609-1616.
50. Mega J.L., Stitziel N.O., Smith J.G., et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015, 385(9984):2264-2271.
51. Mirosevic Skvrce N., Bozina N., Zibar L., Barisic I., Pejnovic L., Macolic Sarinic V. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. Pharmacogenomics 2013, 14(12):1419-1431.
52. Badve S.V., Roberts M.A., Hawley C.M., et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011, 58(11):1152-1161.
53. Baber U., Howard V.J., Halperin J.L., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Circ Arrhythm Electrophysiol 2011, 4(1):26-32.
54. Chiu D.Y., Sinha S., Kalra P.A., Green D. Sudden cardiac death in haemodialysis patients: preventative options. Nephrology (Carlton) 2014, 19(12):740-749.
55. Frankenfield D.L., Weinhandl E.D., Powers C.A., Howell B.L., Herzog C.A., St Peter W.L. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. Am J Kidney Dis 2012, 59(5):670-681.
56. Blake C.M., Kharasch E.D., Schwab M., Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther 2013, 94(3):394-399.
57. Hamadeh I.S., Langaee T.Y., Dwivedi R., et al. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther 2014, 96(2):175-181.
58. Rau T., Wuttke H., Michels L.M., et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 2009, 85(3):269-272.
59. Batty J.A., Hall A.S., White H.L., et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. Clin Pharmacol Ther 2014, 95(3):321-330.
60. Bijl M.J., Visser L.E., van Schaik R.H., et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 2009, 85(1):45-50.
61. Fux R., Morike K., Prohmer A.M., et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005, 78(4):378-387.
62. Sehrt D., Meineke I., Tzvetkov M., Gultepe S., Brockmoller J. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 2011, 12(6):783-795.
63. Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., Pauly D.F. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003, 74(1):44-52.
64. Pacanowski M.A., Gong Y., Cooper-Dehoff R.M., et al. Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008, 84(6):715-721.
65. Rau T., Dungen H.D., Edelmann F., et al. Impact of the beta1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther 2012, 92(1):21-28.
66. Terra S.G., Hamilton K.K., Pauly D.F., et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005, 15(4):227-234.
67. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 2006, 103(30):11288-11293.
68. Aleong R.G., Sauer W.H., Sauer W.H., et al. Prevention of atrial fibrillation by bucindolol is dependent on the beta(1)389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail 2013, 1(4):338-344.
69. Bristow M.R., Murphy G.A., Krause-Steinrauf H., et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010, 3(1):21-28.
70. Sehnert A.J., Daniels S.E., Elashoff M., et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008, 52(8):644-651.
71. Liggett S.B., Cresci S., Kelly R.J., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008, 14(5):510-517.
72. Cresci S., Kelly R.J., Cappola T.P., et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 2009, 54(5):432-444.
73. Relling M.V., Gardner E.E., Sandborn W.J., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011, 89(3):387-391.
74. Birdwell K.A., Decker B., Barbarino J.M., et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 2015, 98(1):19-24.
75. Rojas L., Neumann I., Herrero M.J., et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J 2015, 15(1):38-48.
76. Thervet E., Loriot M.A., Barbier S., et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010, 87(6):721-726.